Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Evidence Summary There is currently insufficient evidence of consistent magnesium depletion directly caused by GLP-1 therapy
For example, in the treatment of Alzheimers diseases (AD) and Parkinsons diseases (PD), GLP-1RAs have shown potential in slowing disease progression, while their anti-inflammatory properties offer new hope for conditions such as osteoarthritis (OA), rheumatoid arthritis (RA) and cardiovascular diseases.13,14,15 By integrating the latest clinical trial data, we explore the efficacy of GLP-1RAs in treating diseases of the nervous, cardiovascular, endocrine, and digestive systems
Incretin Physiology GLP-1 is made and released by the enteroendocrine L-cells, which are found throughout the small and large intestines, with higher concentration in the ileum
These may include issues related to intestinal permeability, irritation, or imbalance within the gut environment
J Alzheimers Dis 31(4):751758 Ataie A, Sabetkasaei M, Haghparast A, Moghaddam AH, Kazeminejad B (2010) Neuroprotective effects of the polyphenolic antioxidant agent, curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat
US$ 27.07
US$ 20.29
US$ 24.53
US$ 24.64
US$ 27.80
US$ 26.40
US$ 22.62
